nodes	percent_of_prediction	percent_of_DWPC	metapath
Topotecan—Topoisomerase Inhibitors—Epirubicin—bone cancer	0.258	0.519	CiPCiCtD
Topotecan—Topoisomerase Inhibitors—Doxorubicin—bone cancer	0.238	0.481	CiPCiCtD
Topotecan—peripheral nervous system neoplasm—bone cancer	0.144	0.506	CtDrD
Topotecan—lung cancer—bone cancer	0.141	0.494	CtDrD
Topotecan—CYP3A4—bone cancer	0.11	1	CbGaD
Topotecan—ABCG2—Carboplatin—bone cancer	0.021	0.262	CbGbCtD
Topotecan—ABCG2—Cisplatin—bone cancer	0.018	0.224	CbGbCtD
Topotecan—ABCG2—Doxorubicin—bone cancer	0.012	0.15	CbGbCtD
Topotecan—ABCG2—Methotrexate—bone cancer	0.0117	0.145	CbGbCtD
Topotecan—ABCB1—Cisplatin—bone cancer	0.00647	0.0807	CbGbCtD
Topotecan—ABCB1—Doxorubicin—bone cancer	0.00434	0.054	CbGbCtD
Topotecan—ABCB1—Methotrexate—bone cancer	0.0042	0.0524	CbGbCtD
Topotecan—CYP3A4—Doxorubicin—bone cancer	0.0026	0.0324	CbGbCtD
Topotecan—Irinotecan—CYP3A4—bone cancer	0.000522	1	CrCbGaD
Topotecan—ABCG2—HIF-2-alpha transcription factor network—CITED2—bone cancer	0.000301	0.107	CbGpPWpGaD
Topotecan—TOP1—Circadian rythm related genes—TNFRSF11A—bone cancer	0.000246	0.0875	CbGpPWpGaD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.000177	0.063	CbGpPWpGaD
Topotecan—ABCG2—Irinotecan Pathway—CYP3A4—bone cancer	0.000121	0.0431	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000112	0.0397	CbGpPWpGaD
Topotecan—Bone pain—Doxorubicin—bone cancer	0.000103	0.00403	CcSEcCtD
Topotecan—ABCB1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000102	0.0364	CbGpPWpGaD
Topotecan—Colitis—Epirubicin—bone cancer	0.000102	0.004	CcSEcCtD
Topotecan—Neuropathy—Epirubicin—bone cancer	0.0001	0.00392	CcSEcCtD
Topotecan—Sepsis—Methotrexate—bone cancer	9.88e-05	0.00387	CcSEcCtD
Topotecan—Pulmonary embolism—Doxorubicin—bone cancer	9.86e-05	0.00386	CcSEcCtD
Topotecan—Rash maculo-papular—Epirubicin—bone cancer	9.68e-05	0.00379	CcSEcCtD
Topotecan—Neoplasm—Epirubicin—bone cancer	9.63e-05	0.00377	CcSEcCtD
Topotecan—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	9.59e-05	0.0341	CbGpPWpGaD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—CITED2—bone cancer	9.57e-05	0.0341	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	9.48e-05	0.0337	CbGpPWpGaD
Topotecan—Colitis—Doxorubicin—bone cancer	9.46e-05	0.0037	CcSEcCtD
Topotecan—Immune system disorder—Cisplatin—bone cancer	9.41e-05	0.00368	CcSEcCtD
Topotecan—Mediastinal disorder—Cisplatin—bone cancer	9.39e-05	0.00368	CcSEcCtD
Topotecan—Neuropathy—Doxorubicin—bone cancer	9.25e-05	0.00362	CcSEcCtD
Topotecan—Sepsis—Epirubicin—bone cancer	9.24e-05	0.00362	CcSEcCtD
Topotecan—Alopecia—Cisplatin—bone cancer	9.2e-05	0.0036	CcSEcCtD
Topotecan—Malnutrition—Cisplatin—bone cancer	9.07e-05	0.00355	CcSEcCtD
Topotecan—Rash maculo-papular—Doxorubicin—bone cancer	8.96e-05	0.00351	CcSEcCtD
Topotecan—Neoplasm—Doxorubicin—bone cancer	8.91e-05	0.00349	CcSEcCtD
Topotecan—Muscle spasms—Cisplatin—bone cancer	8.72e-05	0.00341	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	8.63e-05	0.0307	CbGpPWpGaD
Topotecan—Sepsis—Doxorubicin—bone cancer	8.55e-05	0.00335	CcSEcCtD
Topotecan—Anaphylactoid reaction—Methotrexate—bone cancer	8.54e-05	0.00334	CcSEcCtD
Topotecan—Lethargy—Methotrexate—bone cancer	8.43e-05	0.0033	CcSEcCtD
Topotecan—Ill-defined disorder—Cisplatin—bone cancer	8.41e-05	0.00329	CcSEcCtD
Topotecan—Anaemia—Cisplatin—bone cancer	8.38e-05	0.00328	CcSEcCtD
Topotecan—TOP1—Circadian rythm related genes—GNA11—bone cancer	8.33e-05	0.0296	CbGpPWpGaD
Topotecan—TOP1—Circadian rythm related genes—EZH2—bone cancer	8.29e-05	0.0295	CbGpPWpGaD
Topotecan—Malaise—Cisplatin—bone cancer	8.18e-05	0.0032	CcSEcCtD
Topotecan—Leukopenia—Cisplatin—bone cancer	8.12e-05	0.00318	CcSEcCtD
Topotecan—Dermatitis bullous—Epirubicin—bone cancer	8.09e-05	0.00317	CcSEcCtD
Topotecan—Anaphylactoid reaction—Epirubicin—bone cancer	7.99e-05	0.00313	CcSEcCtD
Topotecan—Lethargy—Epirubicin—bone cancer	7.89e-05	0.00309	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	7.86e-05	0.028	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	7.76e-05	0.0276	CbGpPWpGaD
Topotecan—Myalgia—Cisplatin—bone cancer	7.72e-05	0.00302	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	7.67e-05	0.003	CcSEcCtD
Topotecan—Discomfort—Cisplatin—bone cancer	7.63e-05	0.00299	CcSEcCtD
Topotecan—Dermatitis bullous—Doxorubicin—bone cancer	7.48e-05	0.00293	CcSEcCtD
Topotecan—Anaphylactic shock—Cisplatin—bone cancer	7.4e-05	0.0029	CcSEcCtD
Topotecan—Anaphylactoid reaction—Doxorubicin—bone cancer	7.39e-05	0.00289	CcSEcCtD
Topotecan—Cardiac arrest—Epirubicin—bone cancer	7.35e-05	0.00288	CcSEcCtD
Topotecan—Infection—Cisplatin—bone cancer	7.35e-05	0.00288	CcSEcCtD
Topotecan—Lethargy—Doxorubicin—bone cancer	7.3e-05	0.00286	CcSEcCtD
Topotecan—Nervous system disorder—Cisplatin—bone cancer	7.26e-05	0.00284	CcSEcCtD
Topotecan—Thrombocytopenia—Cisplatin—bone cancer	7.24e-05	0.00284	CcSEcCtD
Topotecan—ABCG2—Fluoropyrimidine Activity—DHFR—bone cancer	7.19e-05	0.0256	CbGpPWpGaD
Topotecan—Skin disorder—Cisplatin—bone cancer	7.19e-05	0.00281	CcSEcCtD
Topotecan—Hyperhidrosis—Cisplatin—bone cancer	7.15e-05	0.0028	CcSEcCtD
Topotecan—Anorexia—Cisplatin—bone cancer	7.05e-05	0.00276	CcSEcCtD
Topotecan—Aspartate aminotransferase increased—Epirubicin—bone cancer	6.96e-05	0.00273	CcSEcCtD
Topotecan—Alanine aminotransferase increased—Epirubicin—bone cancer	6.82e-05	0.00267	CcSEcCtD
Topotecan—Cardiac arrest—Doxorubicin—bone cancer	6.8e-05	0.00266	CcSEcCtD
Topotecan—Pancytopenia—Methotrexate—bone cancer	6.78e-05	0.00265	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Cisplatin—bone cancer	6.74e-05	0.00264	CcSEcCtD
Topotecan—Neutropenia—Methotrexate—bone cancer	6.68e-05	0.00261	CcSEcCtD
Topotecan—Paraesthesia—Cisplatin—bone cancer	6.64e-05	0.0026	CcSEcCtD
Topotecan—Dyspnoea—Cisplatin—bone cancer	6.6e-05	0.00258	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	6.57e-05	0.0234	CbGpPWpGaD
Topotecan—Aspartate aminotransferase increased—Doxorubicin—bone cancer	6.44e-05	0.00252	CcSEcCtD
Topotecan—Decreased appetite—Cisplatin—bone cancer	6.43e-05	0.00252	CcSEcCtD
Topotecan—Pneumonia—Methotrexate—bone cancer	6.4e-05	0.00251	CcSEcCtD
Topotecan—Gastrointestinal disorder—Cisplatin—bone cancer	6.39e-05	0.0025	CcSEcCtD
Topotecan—Infestation NOS—Methotrexate—bone cancer	6.37e-05	0.00249	CcSEcCtD
Topotecan—Infestation—Methotrexate—bone cancer	6.37e-05	0.00249	CcSEcCtD
Topotecan—Pancytopenia—Epirubicin—bone cancer	6.35e-05	0.00248	CcSEcCtD
Topotecan—Pain—Cisplatin—bone cancer	6.33e-05	0.00248	CcSEcCtD
Topotecan—Alanine aminotransferase increased—Doxorubicin—bone cancer	6.31e-05	0.00247	CcSEcCtD
Topotecan—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	6.28e-05	0.0223	CbGpPWpGaD
Topotecan—Neutropenia—Epirubicin—bone cancer	6.25e-05	0.00245	CcSEcCtD
Topotecan—Stomatitis—Methotrexate—bone cancer	6.21e-05	0.00243	CcSEcCtD
Topotecan—Sweating—Methotrexate—bone cancer	6.1e-05	0.00239	CcSEcCtD
Topotecan—Feeling abnormal—Cisplatin—bone cancer	6.1e-05	0.00239	CcSEcCtD
Topotecan—Weight increased—Epirubicin—bone cancer	6.08e-05	0.00238	CcSEcCtD
Topotecan—Hepatobiliary disease—Methotrexate—bone cancer	6.02e-05	0.00236	CcSEcCtD
Topotecan—Epistaxis—Methotrexate—bone cancer	6e-05	0.00235	CcSEcCtD
Topotecan—Pneumonia—Epirubicin—bone cancer	5.99e-05	0.00235	CcSEcCtD
Topotecan—Infestation—Epirubicin—bone cancer	5.96e-05	0.00233	CcSEcCtD
Topotecan—Infestation NOS—Epirubicin—bone cancer	5.96e-05	0.00233	CcSEcCtD
Topotecan—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	5.91e-05	0.021	CbGpPWpGaD
Topotecan—Pancytopenia—Doxorubicin—bone cancer	5.87e-05	0.0023	CcSEcCtD
Topotecan—Body temperature increased—Cisplatin—bone cancer	5.85e-05	0.00229	CcSEcCtD
Topotecan—Neuropathy peripheral—Epirubicin—bone cancer	5.84e-05	0.00229	CcSEcCtD
Topotecan—Stomatitis—Epirubicin—bone cancer	5.81e-05	0.00227	CcSEcCtD
Topotecan—Neutropenia—Doxorubicin—bone cancer	5.78e-05	0.00226	CcSEcCtD
Topotecan—Haemoglobin—Methotrexate—bone cancer	5.74e-05	0.00225	CcSEcCtD
Topotecan—Haemorrhage—Methotrexate—bone cancer	5.72e-05	0.00224	CcSEcCtD
Topotecan—Sweating—Epirubicin—bone cancer	5.71e-05	0.00224	CcSEcCtD
Topotecan—Pharyngitis—Methotrexate—bone cancer	5.67e-05	0.00222	CcSEcCtD
Topotecan—Hepatobiliary disease—Epirubicin—bone cancer	5.63e-05	0.00221	CcSEcCtD
Topotecan—Weight increased—Doxorubicin—bone cancer	5.63e-05	0.0022	CcSEcCtD
Topotecan—Epistaxis—Epirubicin—bone cancer	5.62e-05	0.0022	CcSEcCtD
Topotecan—ABCB1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	5.6e-05	0.0199	CbGpPWpGaD
Topotecan—Pneumonia—Doxorubicin—bone cancer	5.54e-05	0.00217	CcSEcCtD
Topotecan—Infestation NOS—Doxorubicin—bone cancer	5.51e-05	0.00216	CcSEcCtD
Topotecan—Infestation—Doxorubicin—bone cancer	5.51e-05	0.00216	CcSEcCtD
Topotecan—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	5.51e-05	0.0196	CbGpPWpGaD
Topotecan—Hypersensitivity—Cisplatin—bone cancer	5.45e-05	0.00213	CcSEcCtD
Topotecan—Neuropathy peripheral—Doxorubicin—bone cancer	5.4e-05	0.00212	CcSEcCtD
Topotecan—Haemoglobin—Epirubicin—bone cancer	5.38e-05	0.0021	CcSEcCtD
Topotecan—Stomatitis—Doxorubicin—bone cancer	5.37e-05	0.0021	CcSEcCtD
Topotecan—Rhinitis—Epirubicin—bone cancer	5.36e-05	0.0021	CcSEcCtD
Topotecan—Haemorrhage—Epirubicin—bone cancer	5.35e-05	0.00209	CcSEcCtD
Topotecan—Hypoaesthesia—Epirubicin—bone cancer	5.32e-05	0.00208	CcSEcCtD
Topotecan—Asthenia—Cisplatin—bone cancer	5.31e-05	0.00208	CcSEcCtD
Topotecan—Pharyngitis—Epirubicin—bone cancer	5.31e-05	0.00208	CcSEcCtD
Topotecan—Sweating—Doxorubicin—bone cancer	5.28e-05	0.00207	CcSEcCtD
Topotecan—Hepatobiliary disease—Doxorubicin—bone cancer	5.21e-05	0.00204	CcSEcCtD
Topotecan—Epistaxis—Doxorubicin—bone cancer	5.2e-05	0.00204	CcSEcCtD
Topotecan—Angiopathy—Methotrexate—bone cancer	5.19e-05	0.00203	CcSEcCtD
Topotecan—Immune system disorder—Methotrexate—bone cancer	5.16e-05	0.00202	CcSEcCtD
Topotecan—Mediastinal disorder—Methotrexate—bone cancer	5.15e-05	0.00202	CcSEcCtD
Topotecan—Chills—Methotrexate—bone cancer	5.13e-05	0.00201	CcSEcCtD
Topotecan—Diarrhoea—Cisplatin—bone cancer	5.06e-05	0.00198	CcSEcCtD
Topotecan—Alopecia—Methotrexate—bone cancer	5.05e-05	0.00198	CcSEcCtD
Topotecan—Malnutrition—Methotrexate—bone cancer	4.98e-05	0.00195	CcSEcCtD
Topotecan—Haemoglobin—Doxorubicin—bone cancer	4.97e-05	0.00195	CcSEcCtD
Topotecan—Rhinitis—Doxorubicin—bone cancer	4.96e-05	0.00194	CcSEcCtD
Topotecan—Haemorrhage—Doxorubicin—bone cancer	4.95e-05	0.00194	CcSEcCtD
Topotecan—Hypoaesthesia—Doxorubicin—bone cancer	4.92e-05	0.00193	CcSEcCtD
Topotecan—Pharyngitis—Doxorubicin—bone cancer	4.91e-05	0.00192	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	4.87e-05	0.0173	CbGpPWpGaD
Topotecan—Angiopathy—Epirubicin—bone cancer	4.85e-05	0.0019	CcSEcCtD
Topotecan—Immune system disorder—Epirubicin—bone cancer	4.83e-05	0.00189	CcSEcCtD
Topotecan—Mediastinal disorder—Epirubicin—bone cancer	4.82e-05	0.00189	CcSEcCtD
Topotecan—Back pain—Methotrexate—bone cancer	4.81e-05	0.00188	CcSEcCtD
Topotecan—Chills—Epirubicin—bone cancer	4.8e-05	0.00188	CcSEcCtD
Topotecan—Alopecia—Epirubicin—bone cancer	4.73e-05	0.00185	CcSEcCtD
Topotecan—Vomiting—Cisplatin—bone cancer	4.7e-05	0.00184	CcSEcCtD
Topotecan—TOP1—Circadian rythm related genes—CDK4—bone cancer	4.68e-05	0.0167	CbGpPWpGaD
Topotecan—Rash—Cisplatin—bone cancer	4.67e-05	0.00183	CcSEcCtD
Topotecan—Dermatitis—Cisplatin—bone cancer	4.66e-05	0.00182	CcSEcCtD
Topotecan—Malnutrition—Epirubicin—bone cancer	4.66e-05	0.00182	CcSEcCtD
Topotecan—Ill-defined disorder—Methotrexate—bone cancer	4.62e-05	0.00181	CcSEcCtD
Topotecan—Anaemia—Methotrexate—bone cancer	4.6e-05	0.0018	CcSEcCtD
Topotecan—Back pain—Epirubicin—bone cancer	4.5e-05	0.00176	CcSEcCtD
Topotecan—Angiopathy—Doxorubicin—bone cancer	4.49e-05	0.00176	CcSEcCtD
Topotecan—Malaise—Methotrexate—bone cancer	4.49e-05	0.00176	CcSEcCtD
Topotecan—Muscle spasms—Epirubicin—bone cancer	4.48e-05	0.00175	CcSEcCtD
Topotecan—Immune system disorder—Doxorubicin—bone cancer	4.47e-05	0.00175	CcSEcCtD
Topotecan—Mediastinal disorder—Doxorubicin—bone cancer	4.46e-05	0.00175	CcSEcCtD
Topotecan—Leukopenia—Methotrexate—bone cancer	4.45e-05	0.00174	CcSEcCtD
Topotecan—Chills—Doxorubicin—bone cancer	4.44e-05	0.00174	CcSEcCtD
Topotecan—Nausea—Cisplatin—bone cancer	4.4e-05	0.00172	CcSEcCtD
Topotecan—Alopecia—Doxorubicin—bone cancer	4.37e-05	0.00171	CcSEcCtD
Topotecan—Cough—Methotrexate—bone cancer	4.34e-05	0.0017	CcSEcCtD
Topotecan—Ill-defined disorder—Epirubicin—bone cancer	4.32e-05	0.00169	CcSEcCtD
Topotecan—Malnutrition—Doxorubicin—bone cancer	4.31e-05	0.00169	CcSEcCtD
Topotecan—Anaemia—Epirubicin—bone cancer	4.3e-05	0.00168	CcSEcCtD
Topotecan—Chest pain—Methotrexate—bone cancer	4.24e-05	0.00166	CcSEcCtD
Topotecan—Arthralgia—Methotrexate—bone cancer	4.24e-05	0.00166	CcSEcCtD
Topotecan—Myalgia—Methotrexate—bone cancer	4.24e-05	0.00166	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	4.21e-05	0.00165	CcSEcCtD
Topotecan—Malaise—Epirubicin—bone cancer	4.2e-05	0.00164	CcSEcCtD
Topotecan—Discomfort—Methotrexate—bone cancer	4.18e-05	0.00164	CcSEcCtD
Topotecan—Leukopenia—Epirubicin—bone cancer	4.17e-05	0.00163	CcSEcCtD
Topotecan—Back pain—Doxorubicin—bone cancer	4.17e-05	0.00163	CcSEcCtD
Topotecan—Muscle spasms—Doxorubicin—bone cancer	4.14e-05	0.00162	CcSEcCtD
Topotecan—Cough—Epirubicin—bone cancer	4.06e-05	0.00159	CcSEcCtD
Topotecan—Anaphylactic shock—Methotrexate—bone cancer	4.06e-05	0.00159	CcSEcCtD
Topotecan—Infection—Methotrexate—bone cancer	4.03e-05	0.00158	CcSEcCtD
Topotecan—Ill-defined disorder—Doxorubicin—bone cancer	4e-05	0.00157	CcSEcCtD
Topotecan—Nervous system disorder—Methotrexate—bone cancer	3.98e-05	0.00156	CcSEcCtD
Topotecan—Anaemia—Doxorubicin—bone cancer	3.98e-05	0.00156	CcSEcCtD
Topotecan—Thrombocytopenia—Methotrexate—bone cancer	3.98e-05	0.00156	CcSEcCtD
Topotecan—Myalgia—Epirubicin—bone cancer	3.96e-05	0.00155	CcSEcCtD
Topotecan—Arthralgia—Epirubicin—bone cancer	3.96e-05	0.00155	CcSEcCtD
Topotecan—Chest pain—Epirubicin—bone cancer	3.96e-05	0.00155	CcSEcCtD
Topotecan—Skin disorder—Methotrexate—bone cancer	3.94e-05	0.00154	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	3.94e-05	0.00154	CcSEcCtD
Topotecan—Hyperhidrosis—Methotrexate—bone cancer	3.93e-05	0.00154	CcSEcCtD
Topotecan—Discomfort—Epirubicin—bone cancer	3.92e-05	0.00153	CcSEcCtD
Topotecan—Malaise—Doxorubicin—bone cancer	3.88e-05	0.00152	CcSEcCtD
Topotecan—Anorexia—Methotrexate—bone cancer	3.87e-05	0.00152	CcSEcCtD
Topotecan—Leukopenia—Doxorubicin—bone cancer	3.86e-05	0.00151	CcSEcCtD
Topotecan—Anaphylactic shock—Epirubicin—bone cancer	3.8e-05	0.00149	CcSEcCtD
Topotecan—Infection—Epirubicin—bone cancer	3.78e-05	0.00148	CcSEcCtD
Topotecan—Cough—Doxorubicin—bone cancer	3.76e-05	0.00147	CcSEcCtD
Topotecan—Nervous system disorder—Epirubicin—bone cancer	3.73e-05	0.00146	CcSEcCtD
Topotecan—Thrombocytopenia—Epirubicin—bone cancer	3.72e-05	0.00146	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Methotrexate—bone cancer	3.7e-05	0.00145	CcSEcCtD
Topotecan—Skin disorder—Epirubicin—bone cancer	3.69e-05	0.00145	CcSEcCtD
Topotecan—Hyperhidrosis—Epirubicin—bone cancer	3.67e-05	0.00144	CcSEcCtD
Topotecan—Chest pain—Doxorubicin—bone cancer	3.67e-05	0.00144	CcSEcCtD
Topotecan—Arthralgia—Doxorubicin—bone cancer	3.67e-05	0.00144	CcSEcCtD
Topotecan—Myalgia—Doxorubicin—bone cancer	3.67e-05	0.00144	CcSEcCtD
Topotecan—Paraesthesia—Methotrexate—bone cancer	3.65e-05	0.00143	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	3.64e-05	0.00143	CcSEcCtD
Topotecan—Discomfort—Doxorubicin—bone cancer	3.62e-05	0.00142	CcSEcCtD
Topotecan—Anorexia—Epirubicin—bone cancer	3.62e-05	0.00142	CcSEcCtD
Topotecan—Dyspnoea—Methotrexate—bone cancer	3.62e-05	0.00142	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	3.61e-05	0.0129	CbGpPWpGaD
Topotecan—Dyspepsia—Methotrexate—bone cancer	3.57e-05	0.0014	CcSEcCtD
Topotecan—Decreased appetite—Methotrexate—bone cancer	3.53e-05	0.00138	CcSEcCtD
Topotecan—Anaphylactic shock—Doxorubicin—bone cancer	3.52e-05	0.00138	CcSEcCtD
Topotecan—Gastrointestinal disorder—Methotrexate—bone cancer	3.51e-05	0.00137	CcSEcCtD
Topotecan—Fatigue—Methotrexate—bone cancer	3.5e-05	0.00137	CcSEcCtD
Topotecan—Infection—Doxorubicin—bone cancer	3.49e-05	0.00137	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	3.48e-05	0.0124	CbGpPWpGaD
Topotecan—Pain—Methotrexate—bone cancer	3.47e-05	0.00136	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Epirubicin—bone cancer	3.46e-05	0.00136	CcSEcCtD
Topotecan—Nervous system disorder—Doxorubicin—bone cancer	3.45e-05	0.00135	CcSEcCtD
Topotecan—Thrombocytopenia—Doxorubicin—bone cancer	3.44e-05	0.00135	CcSEcCtD
Topotecan—Skin disorder—Doxorubicin—bone cancer	3.42e-05	0.00134	CcSEcCtD
Topotecan—Paraesthesia—Epirubicin—bone cancer	3.41e-05	0.00134	CcSEcCtD
Topotecan—Hyperhidrosis—Doxorubicin—bone cancer	3.4e-05	0.00133	CcSEcCtD
Topotecan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	3.39e-05	0.0121	CbGpPWpGaD
Topotecan—Dyspnoea—Epirubicin—bone cancer	3.39e-05	0.00133	CcSEcCtD
Topotecan—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	3.38e-05	0.012	CbGpPWpGaD
Topotecan—Anorexia—Doxorubicin—bone cancer	3.35e-05	0.00131	CcSEcCtD
Topotecan—Feeling abnormal—Methotrexate—bone cancer	3.35e-05	0.00131	CcSEcCtD
Topotecan—Dyspepsia—Epirubicin—bone cancer	3.34e-05	0.00131	CcSEcCtD
Topotecan—Gastrointestinal pain—Methotrexate—bone cancer	3.32e-05	0.0013	CcSEcCtD
Topotecan—Decreased appetite—Epirubicin—bone cancer	3.3e-05	0.00129	CcSEcCtD
Topotecan—Gastrointestinal disorder—Epirubicin—bone cancer	3.28e-05	0.00128	CcSEcCtD
Topotecan—Fatigue—Epirubicin—bone cancer	3.28e-05	0.00128	CcSEcCtD
Topotecan—Pain—Epirubicin—bone cancer	3.25e-05	0.00127	CcSEcCtD
Topotecan—Constipation—Epirubicin—bone cancer	3.25e-05	0.00127	CcSEcCtD
Topotecan—Urticaria—Methotrexate—bone cancer	3.23e-05	0.00126	CcSEcCtD
Topotecan—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	3.22e-05	0.0114	CbGpPWpGaD
Topotecan—Abdominal pain—Methotrexate—bone cancer	3.21e-05	0.00126	CcSEcCtD
Topotecan—Body temperature increased—Methotrexate—bone cancer	3.21e-05	0.00126	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Doxorubicin—bone cancer	3.2e-05	0.00125	CcSEcCtD
Topotecan—Paraesthesia—Doxorubicin—bone cancer	3.16e-05	0.00124	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	3.14e-05	0.0112	CbGpPWpGaD
Topotecan—Dyspnoea—Doxorubicin—bone cancer	3.13e-05	0.00123	CcSEcCtD
Topotecan—Feeling abnormal—Epirubicin—bone cancer	3.13e-05	0.00123	CcSEcCtD
Topotecan—Gastrointestinal pain—Epirubicin—bone cancer	3.11e-05	0.00122	CcSEcCtD
Topotecan—Dyspepsia—Doxorubicin—bone cancer	3.09e-05	0.00121	CcSEcCtD
Topotecan—Decreased appetite—Doxorubicin—bone cancer	3.06e-05	0.0012	CcSEcCtD
Topotecan—Gastrointestinal disorder—Doxorubicin—bone cancer	3.04e-05	0.00119	CcSEcCtD
Topotecan—Fatigue—Doxorubicin—bone cancer	3.03e-05	0.00119	CcSEcCtD
Topotecan—Urticaria—Epirubicin—bone cancer	3.02e-05	0.00118	CcSEcCtD
Topotecan—TOP1—Circadian rythm related genes—JUN—bone cancer	3.02e-05	0.0107	CbGpPWpGaD
Topotecan—Constipation—Doxorubicin—bone cancer	3.01e-05	0.00118	CcSEcCtD
Topotecan—Pain—Doxorubicin—bone cancer	3.01e-05	0.00118	CcSEcCtD
Topotecan—Abdominal pain—Epirubicin—bone cancer	3e-05	0.00118	CcSEcCtD
Topotecan—Body temperature increased—Epirubicin—bone cancer	3e-05	0.00118	CcSEcCtD
Topotecan—Hypersensitivity—Methotrexate—bone cancer	2.99e-05	0.00117	CcSEcCtD
Topotecan—Asthenia—Methotrexate—bone cancer	2.91e-05	0.00114	CcSEcCtD
Topotecan—Feeling abnormal—Doxorubicin—bone cancer	2.9e-05	0.00113	CcSEcCtD
Topotecan—Gastrointestinal pain—Doxorubicin—bone cancer	2.88e-05	0.00113	CcSEcCtD
Topotecan—Pruritus—Methotrexate—bone cancer	2.87e-05	0.00112	CcSEcCtD
Topotecan—Hypersensitivity—Epirubicin—bone cancer	2.8e-05	0.0011	CcSEcCtD
Topotecan—Urticaria—Doxorubicin—bone cancer	2.79e-05	0.00109	CcSEcCtD
Topotecan—Body temperature increased—Doxorubicin—bone cancer	2.78e-05	0.00109	CcSEcCtD
Topotecan—Abdominal pain—Doxorubicin—bone cancer	2.78e-05	0.00109	CcSEcCtD
Topotecan—Diarrhoea—Methotrexate—bone cancer	2.78e-05	0.00109	CcSEcCtD
Topotecan—Asthenia—Epirubicin—bone cancer	2.73e-05	0.00107	CcSEcCtD
Topotecan—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	2.7e-05	0.00962	CbGpPWpGaD
Topotecan—Pruritus—Epirubicin—bone cancer	2.69e-05	0.00105	CcSEcCtD
Topotecan—Dizziness—Methotrexate—bone cancer	2.69e-05	0.00105	CcSEcCtD
Topotecan—Diarrhoea—Epirubicin—bone cancer	2.6e-05	0.00102	CcSEcCtD
Topotecan—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	2.59e-05	0.00922	CbGpPWpGaD
Topotecan—Hypersensitivity—Doxorubicin—bone cancer	2.59e-05	0.00101	CcSEcCtD
Topotecan—Vomiting—Methotrexate—bone cancer	2.58e-05	0.00101	CcSEcCtD
Topotecan—Rash—Methotrexate—bone cancer	2.56e-05	0.001	CcSEcCtD
Topotecan—Dermatitis—Methotrexate—bone cancer	2.56e-05	0.001	CcSEcCtD
Topotecan—Headache—Methotrexate—bone cancer	2.54e-05	0.000996	CcSEcCtD
Topotecan—Asthenia—Doxorubicin—bone cancer	2.52e-05	0.000988	CcSEcCtD
Topotecan—Dizziness—Epirubicin—bone cancer	2.51e-05	0.000984	CcSEcCtD
Topotecan—Pruritus—Doxorubicin—bone cancer	2.49e-05	0.000974	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	2.47e-05	0.00879	CbGpPWpGaD
Topotecan—Vomiting—Epirubicin—bone cancer	2.42e-05	0.000946	CcSEcCtD
Topotecan—Nausea—Methotrexate—bone cancer	2.41e-05	0.000944	CcSEcCtD
Topotecan—Diarrhoea—Doxorubicin—bone cancer	2.41e-05	0.000942	CcSEcCtD
Topotecan—Rash—Epirubicin—bone cancer	2.4e-05	0.000938	CcSEcCtD
Topotecan—Dermatitis—Epirubicin—bone cancer	2.39e-05	0.000937	CcSEcCtD
Topotecan—Headache—Epirubicin—bone cancer	2.38e-05	0.000932	CcSEcCtD
Topotecan—Dizziness—Doxorubicin—bone cancer	2.32e-05	0.00091	CcSEcCtD
Topotecan—Nausea—Epirubicin—bone cancer	2.26e-05	0.000884	CcSEcCtD
Topotecan—Vomiting—Doxorubicin—bone cancer	2.24e-05	0.000875	CcSEcCtD
Topotecan—Rash—Doxorubicin—bone cancer	2.22e-05	0.000868	CcSEcCtD
Topotecan—Dermatitis—Doxorubicin—bone cancer	2.21e-05	0.000867	CcSEcCtD
Topotecan—Headache—Doxorubicin—bone cancer	2.2e-05	0.000862	CcSEcCtD
Topotecan—Nausea—Doxorubicin—bone cancer	2.09e-05	0.000818	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.07e-05	0.00738	CbGpPWpGaD
Topotecan—TOP1—Circadian rythm related genes—TP53—bone cancer	1.99e-05	0.00708	CbGpPWpGaD
Topotecan—ABCG2—Fluoropyrimidine Activity—TP53—bone cancer	1.61e-05	0.00572	CbGpPWpGaD
Topotecan—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	1.4e-05	0.00499	CbGpPWpGaD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—JUN—bone cancer	1.4e-05	0.00498	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—TUBB4B—bone cancer	1.25e-05	0.00444	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	1.15e-05	0.00408	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—TUBB2A—bone cancer	1.08e-05	0.00383	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	9.75e-06	0.00347	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—NDUFA12—bone cancer	9.75e-06	0.00347	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	8.88e-06	0.00316	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	8.09e-06	0.00288	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—NT5C3A—bone cancer	8.08e-06	0.00287	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	7.98e-06	0.00284	CbGpPWpGaD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	7.56e-06	0.00269	CbGpPWpGaD
Topotecan—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	7.15e-06	0.00255	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	6.76e-06	0.00241	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	6.74e-06	0.0024	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	5.82e-06	0.00207	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—NDUFA12—bone cancer	5.27e-06	0.00188	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	5.01e-06	0.00178	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—GSTP1—bone cancer	4.63e-06	0.00165	CbGpPWpGaD
Topotecan—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	4.57e-06	0.00163	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—NT5C3A—bone cancer	4.37e-06	0.00155	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	3.72e-06	0.00132	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	3.58e-06	0.00128	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—ENO2—bone cancer	3.54e-06	0.00126	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—DHFR—bone cancer	3.28e-06	0.00117	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—NDUFA12—bone cancer	3.25e-06	0.00116	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	3.23e-06	0.00115	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—GNA11—bone cancer	3.07e-06	0.00109	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—CYP3A4—bone cancer	2.78e-06	0.00099	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—NT5C3A—bone cancer	2.69e-06	0.000958	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	2.54e-06	0.000904	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—GSTP1—bone cancer	2.38e-06	0.000847	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.13e-06	0.000759	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—ENO2—bone cancer	1.91e-06	0.000681	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—DHFR—bone cancer	1.78e-06	0.000632	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—GNA11—bone cancer	1.66e-06	0.00059	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—CYP3A4—bone cancer	1.5e-06	0.000535	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—GSTP1—bone cancer	1.29e-06	0.000458	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—PTGS2—bone cancer	1.23e-06	0.000439	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—ENO2—bone cancer	1.18e-06	0.000419	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—DHFR—bone cancer	1.09e-06	0.000389	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—GNA11—bone cancer	1.02e-06	0.000364	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—GSTP1—bone cancer	7.93e-07	0.000282	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—PTGS2—bone cancer	6.66e-07	0.000237	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—PTGS2—bone cancer	4.11e-07	0.000146	CbGpPWpGaD
